Previous close | 3.8150 |
Open | 3.8000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.8000 - 3.9600 |
52-week range | 2.9500 - 8.8470 |
Volume | |
Avg. volume | 9,038 |
Market cap | 21.504M |
Beta (5Y monthly) | 1.92 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.2800 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.67 |
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscapeDOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL event to discuss APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor, on Monday, June 24, 2024 at 9:00 AM ET. To
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represents a key advancement in Aprea’s clinical pipeline DOYLESTOWN, Pa., June 17, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on pre